Denosumab Treatment Does Not Halt Progression of Bone Lesions in Multicentric Carpotarsal Osteolysis Syndrome

Here we report the use of denosumab, a monoclonal antibody against receptor activator of nuclear factor κB ligand (RANKL), as monotherapy for multicentric carpotarsal osteolysis syndrome (MCTO) in an 11.5‐year‐old male with a heterozygous missense mutation in MAFB (c.206C>T; p.Ser69Leu). We treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerman, Melissa A., Francavilla, Michael, Waqar‐Cowles, Lindsay, Levine, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184019/
https://www.ncbi.nlm.nih.gov/pubmed/37197321
http://dx.doi.org/10.1002/jbm4.10729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184019/
https://www.ncbi.nlm.nih.gov/pubmed/37197321
http://dx.doi.org/10.1002/jbm4.10729

Ejemplares similares